Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Integra LifeSciences Corporation
WARNING LETTER
•Integra LifeSciences Corporation•August 22, 2024

Integra LifeSciences Corporation – FDA Warning Letter, Aug 22, 2024

Record Details

The FDA issued a Warning Letter to Integra LifeSciences following inspections at its Mansfield, MA, Plainsboro, NJ, and Princeton, NJ facilities. The firm's neurological and neurosurgical devices were deemed adulterated under 21 U.S.C. § 351(h) due to widespread non-compliance with the Quality System regulation (21 CFR Part 820). Key violations include failures in controlling nonconforming product (21 CFR § 820.90(a)), with inadequate OOS endotoxin investigations and product recalls. Deficiencies were noted in procedures for acceptance activities (21 CFR § 820.80(a)) and finished device acceptance (21 CFR § 820.80(d)), involving unjustified retesting and insufficient pyrogen testing. The corrective and preventive action (CAPA) system (21 CFR § 820.100(a)) was inadequate, with unescalated CAPAs and improper use of quality plans. The firm also failed to review process changes and perform revalidation (21 CFR § 820.75(c)), affecting sterilization and supplier changes. Contamination control (21 CFR § 820.70(e)) was deficient, and critical processes like LAL testing lacked proper validation (21 CFR § 820.75(a)). While Integra initiated CAPAs and recalls, their adequacy is undetermined, with many actions pending into 2025. The FDA demands a comprehensive response within 15 business days addressing systemic issues, warning of potential regulatory actions, including seizure, injunctions, and impacts on device approvals and contracts.

Company
Integra LifeSciences Corporation
Inspection date
August 22, 2024
Product type
Devices
Office
Center for Devices and Radiological Health
Person
  • Sean M. Boyd (Office Director)
View Company Profile

ID · ad10acef-4212-455a-b328-1da9842de1d6

Violation Codes9
21 U.S.C. 321(h)21 U.S.C. 351(h)21 CFR 820.90(a)21 CFR 820.80(a)21 CFR 820.80(d)21 CFR 820.100(a)21 CFR 820.75(c)21 CFR 820.70(e)21 CFR 820.75(a)

Full citation text and observation details available on the Dashboard.

Other documents for Integra LifeSciences Corporation
  • WARNING_LETTER - 2023-05-17May 17, 2023
  • 483 - 2018-07-02July 2, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Integra LifeSciences Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.